Safety and Efficacy of New Biodegradable Polymer-based Sirolimus-Eluting Stents in a Preclinical Model

• Published in: Revista española de cardiología (English ed.) Vol. 70; no. 12; pp. 1059 - 1066
• Main Authors: Pérez de Prado, Armando, Pérez Martínez, Claudia, Cuellas Ramón, Carlos, Regueiro Purriños, Marta, López Benito, María, Gonzalo Orden, José Manuel, Rodríguez Altónaga, José Antonio, Estévez Loureiro, Rodrigo, Benito González, Tomás, Viñuela Baragaño, David, Molina Crisol, María, Amorós Aguilar, Marc, Pérez Serranos, Isabel, Vidal Parreu, Arnau, Benavides Montegordo, Ana, Duocastella Codina, Luis, Fernández Vázquez, Felipe
• Format: Journal Article
• Language: English; Spanish
• Published: Spain 01.12.2017
• Subjects: Cardiovascular; Internal Medicine; drug-eluting stents; MLD; Drug-eluting stent; Vascular healing; Stent farmacoactivo; minimal luminal diameter; BMS; bare-metal stents; Restenosis; Reparación vascular; DES; Modelo preclínico; Reestenosis; Preclinical model
• ISSN: 1885-5857; 1885-5857
• DOI: 10.1016/j.rec.2017.05.021

Abstract Introduction and objectives New drug-eluting stents (DES) designed to overcome the limitations of existing devices should initially be tested in preclinical studies. Our objective was to analyze the safety and efficacy of new biodegradable polymer-based DES compared with bare-metal stents (BMS) and commercially available DES in a model of normal porcine coronary arteries. Methods We randomly implanted 101 stents (BMS and biodegradable polymer-based sirolimus-eluting stents: 3 test stent iterations [BD1, BD2, and BD3], Orsiro, Biomime and Biomatrix) in the coronary arteries of 34 domestic pigs. Angiographic and histomorphometric studies were conducted 1 month (n = 83) and 3 months (n = 18) later. Results The stents were implanted at a stent/artery ratio of 1.31 ± 0.21, with no significant differences between groups. At 1 month, the new test stents (BD1, BD2 and BD3) showed less late loss and angiographic restenosis, as well as lower histologic restenosis and neointimal area ( P < .0005), than the BMS. There were no differences in endothelialization, vascular injury, or inflammation between the new test stents and BMS, although the new stents showed higher fibrin deposition ( P = .0006). At 3 months, all these differences disappeared, except for a lower neointimal area with the new BD1 stent ( P = .027). No differences at any time point were observed between the new test stents and commercially available controls. Conclusions In this preclinical model, the new biodegradable polymer-based DES studied showed less restenosis than BMS and no significant differences in safety or efficacy vs commercially available DES.